Slide 1: Company Presentation: Transforming Lives Through NeuroHealth
Exhibit 99.2 COMPANY PRESENTATION NASDAQ: STIM May 2026 Transforming Lives Through NeuroHealth
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to financial measures prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), from time to time we may use or publicly disclose certain non-GAAP financial measures in the course of our financial presentations, earnin
Slide 4: Unique Patients Treated
245,088 1 Unique Patients Treated As a global leader in neuroscience, Neuronetics is delivering more options 8,805,526 1 Treatments Administered to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. $149M Annual Revenue (2025) (1) Neuronetics, In
Slide 5: A Leader in Mental Health Care
A Leader in Mental Health Care Through its nationwide network of customers and company-run clinics, Neuronetics is facilitating access to leading therapies for mental health conditions. Large patient population poorly served by medication Industry-leading vertically integrated device and clinic offe
Slide 6: Lives Affected by Depression and OCD
Over 29 Million Lives Affected by Depression and OCD Nearly 8 million patients are poorly served by antidepressant medication • Lack of Treatment Efficacy Total Available Market • Intolerable Side Effects Adult Depression (MDD) Adolescent Depression 4 4.3 million suffering 1 29.3 million 21 million
Slide 7: A Uniquely Diversified Business Model
A Uniquely Diversified Business Model Vertical integration provides greater access to mental health treatments nationwide NeuroStar Greenbrook Transcranial Magnetic Stimulation (TMS) Mental Health Services Provider Market Leader in TMS Devices Leading Mental Wellness Care Network Company Confidentia
Slide 8: #1 Physician Recommended TMS
#1 Physician Recommended TMS Dedicated to Practice 1 Market Leader in TMS Success Over 8.4 million treatment Most comprehensive customer sessions performed on over support team in the industry to 1 230,000 patients support over 800 U.S. offices Robust R&D Pipeline Widely Reimbursed rd 3 generation s
Slide 9: SPRAVATO Program
® SPRAVATO Program ® • In March 2019, the FDA approved SPRAVATO (esketamine) nasal spray, in conjunction with an oral antidepressant, for Treatment Resistant Depression in adults and in August 2020, the FDA added a second indication for depressive symptoms in adults with MDD with acute suicidal idea
Slide 10: Significant Commercial Footprint and Scale
Significant Commercial Footprint and Scale Greenbrook NeuroStar TMS 93 Clinics Nationwide 800+ Customer Sites Nationwide Company Confidential 10
Slide 11: Comprehensive Customer Support Team
Strategic Account Comprehensive Customer Managers Support Team Reimbursement Area Sales Specialists & Managers Managers Experienced team Regional Clinical Training Account Managers Managers dedicated to consistent growth and practice success Field Service Customer and Technical Service Support Repre
Slide 12: Positioned to Capitalize on Innovations in Mental Health
Neuronetics is Positioned to Capitalize on Innovations in the Mental Health Space Medication Management Interventional Medical Patients Medication Technology Pending Introduction of Psychedelic Psychotherapy Therapies Company Confidential 12
Slide 13: Key Growth Initiatives for Network Clinics
Key Growth Initiatives for Network Clinics Focus on execution, profitable product diversification & expansion Drive growth in 93 clinics through enhanced RAM clinic Identifying and engagement, leveraging automated referral systems Educating Patients and optimized digital/DTC targeting Expanding the
Slide 14: Key Growth Initiatives for Customer Clinics
Key Growth Initiatives for Customer Clinics Harnessing the power of our proven programs to help more patients in need New Go-To-Market Expanding go-to-market menu through pilot programs Models aimed at addressing customer needs Enhance digital education utilizing social media, blogs, Patient Educati
Slide 15: Poised to Deliver Strong Growth While Improving Cash Flow
Poised to Deliver Strong Growth While Improving Cash Flow th (As of May 5 , 2026) FY 2026 Guidance Revenue $160M to $166M (+7% to +11% YoY) Between 47% and 49% Gross Margin $100M - $105M Operating Expenses includes ~$8.5 million of non-cash stock-based compensation Cash Flow Cash Flow from Operation
Slide 16: Seasoned Senior Leadership Team
Seasoned Senior Leadership Team Dan Reuvers Andrew Macan Cory Anderson Lisa Metzner-Rosas Jeff Jones President & CEO EVP, GC & Chief SVP, Chief SVP, Chief SVP, Chief of Compliance Officer Technology Officer Marketing Officer Operations Company Confidential 16
Slide 17: Financial Overview
Financial Overview Neuronetics transforming lives through NeuroHealth Company Confidential 17
Slide 18: Worldwide Quarterly Revenue
1 Worldwide Quarterly Revenue ($ in ($ in m illions million)s) (As Reported) Q1 2026 Revenue of $34.5M, an 8% increase from Q1 2025 $41.8 $38.1 $37.3 $34.5 $32.0 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 (1) Actual results as reported and filed with the SEC for Neuronetics Company Confidential 18
Slide 19: 2025–2026 U.S. NeuroStar Treatments
2025 – 2026 U.S. NeuroStar Treatments ($ in millions) , , , , , Company Confidential 19
Slide 20: 2025–2026 U.S. Clinic Appointments
2025 – 2026 U.S. Clinic Appointments ($ in millions) , -2.4% vs. , Prior Year , , , Company Confidential 20
Slide 21: Results of Operations
1 Results of Operations ($ in ($ in thousand thousasn)ds) (As Reported) Three Months Ended March 31, 2025 2026 Revenues $31,975 $34,454 YOY Growth 8% Gross Profit $15,738 $16,154 Gross Margin 49% 47% Total Operating Expenses $26,752 $25,149 % of Revenues 84% 73% Loss from Operations ($11,104) ($8,99
Slide 22: Reconciliation Bridge EBITDA to Adjusted EBITDA
Reconciliation Bridge EBITDA to Adjusted EBITDA ($ in thousands) The following table presents the Company’s reconciliation between EBITDA and adjusted EBITDA. These pro formaed re os nu altsss ua mre p tiobnass that management believes are reasonable under the circumstances. However, they are not ne
Slide 23: Financial Position
($ in thousands) Financial Position ($ in thousands) As of March 31, 2026 Cash and Cash Equivalents $13,214 Restricted Cash $5,750 Total Cash $18,964 Other Assets $106,476 Total Assets $125,440 Long-term debt, net $61,297 Convertible Preferred Stock Warrant Liability $0 Convertible Preferred Stock $
Slide 24: Supplemental Information
Supplemental Information Neuronetics, Inc. Company Confidential 24
Slide 25: Supplemental Financial and Operating Information
1 Supplemental Financial and Operating Information ($ in thousands) (As Reported) (1) Actual results as reported and filed with the SEC for Neuronetics Company Confidential 25